arrow
P

Paul J. Ross

University of Southampton
H指数:61
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC plus FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial

预后标志物、生活质量(QoL)和健康价值(V-He)在随机III期、多中心、开放标签的ABC-06临床试验中,接受二线单纯积极症状控制(ASC)或ASC联合奥沙利铂-5-FU化疗(ASC plus FOLFOX)治疗的晚期胆道癌(ABC)中的研究

2026-06-010
OAAI
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

密码子特异性KRAS突变预测转移性结直肠癌中三氟尿苷/替匹拉西的生存益处

2023-03-0244
OAAI
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX , or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

吉西他滨联合卡培他滨、FOLFIRINOX或放化疗治疗边缘可切除胰腺癌患者的即刻手术比较 (ESPAC5): 一项四组、多中心、随机、2期临床试验

2023-02-01143
OAAI
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
2022-10-0443
OAAI
Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors
2021-12-0114
OAAI
Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London
2021-08-1639
OAAI